Hooper, Lundy and Bookman launches IP practice
Hooper, Lundy and Bookman has appointed Andrew Woodmansee to head up a new IP practice at the firm.
Allergan to pay $2.7m to settle antitrust suit over Asacol
A subsidiary of Irish pharmaceutical company Allergan is to pay a combined total of $2.7 million to three organisations that were part of an antitrust class against the drugmaker.
EU requests WTO panel over Turkey’s pharma measures
The European Union has asked the World Trade Organization to establish a panel on Turkey’s measures on pharmaceutical products.
Broad hits out at UC Berkeley in latest CRISPR battle
Tensions appear to be running high in the dispute between the Broad Institute of MIT and Harvard and the University of California, Berkeley (UC Berkeley) over which first invented the CRISPR gene-editing technology.
Bausch Health resolves IP litigation with Teva
Canadian pharmaceutical company Bausch Health and generics maker Teva have resolved their dispute over Apriso (mesalazine), a drug used to treat ulcerative colitis and Crohn's disease.
Trump confounds big pharma with low-cost drugs import plan
In a bid to lower drug prices for American patients, the Trump administration has proposed plans to allow the importation of cheaper drugs from Canada and other countries.
Exact Sciences and Genomic Health in $2.8bn merger
Exact Sciences will acquire Genomic Health in a merger deal worth $2.8 billion.
Alkermes settles with Amneal over opioid dependence treatment
Biopharmaceutical company Alkermes has entered into a settlement and licence agreement with generic maker Amneal Pharmaceuticals to resolve an inter partes review.
IPR of pre-AIA patents isn’t unconstitutional, finds Fed Circuit
In a defeat for biotech company Celgene, the US Court of Appeals for the Federal Circuit has concluded that the retroactive application of inter partes review proceedings to a pre-American Invents Act patent isn’t unconstitutional.
Teva to pay California $69m over pay-for-delay deals
The state of California has secured a $69 million settlement with Teva, which allegedly entered into collusive pay-for-delay agreements with generic competitors.
